FGFR3 is a tyrosine kinase receptor that plays a crucial role in regulating bone and cartilage development through inhibition of chondrocyte proliferation and maturation. The receptor functions by binding fibroblast growth factors and activating downstream signaling pathways including MAPK and PI3K/AKT cascades 1. FGFR3 normally acts as a negative regulator of bone growth, with increased signaling leading to suppressed growth plate chondrocyte proliferation and reduced bone elongation 1. Disease-causing mutations typically result in gain-of-function through enhanced receptor dimerization, stabilization, or increased kinase activity 1. The most common pathogenic variant is G380R, found in over 95% of achondroplasia cases, the most frequent form of human dwarfism affecting more than 250,000 individuals worldwide 23. FGFR3 alterations are also significant in oncology, with mutations found in up to 15-20% of muscle-invasive bladder cancers and as high as 80% in non-muscle invasive bladder cancers, promoting tumorigenesis 45. Additionally, FGFR3-TACC3 fusions occur in 3-4% of glioblastomas, leading to constitutive kinase activation and tumor progression 6. Neurological complications from bone malformations can occur in achondroplasia, particularly affecting the foramen magnum and spinal canal 7.